Dentists in Randolph, VT Accepting Medicare
4 Dentists found. Showing 1 - 4
 Dr. Mark Andrew Luttrell, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 58 S Pleasant St, Randolph, VT 05060 Phone: 802-728-3344 |
Dr. Richard Toyoo Yoshikawa, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 9 School St, Randolph, VT 05060 Phone: 802-728-3008 Fax: 802-728-3008 |
Dr. Christopher Mclean Wilson, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 55 Central Street, Randolph, VT 05060 Phone: 802-728-3343 Fax: 802-276-3538 |
Dr. John Leonard Westbrook, DDS, Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1422 Vt Rt 66, Randolph, VT 05060 Phone: 802-728-9990 Fax: 802-728-3309 |
News Archive
Grifols launches Flebogamma 10% DIF intravenous immune globulin in the U.S.
Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.
FDA approves implantable electronic device that stimulates the diaphragm
The U.S. Food and Drug Administration has announced that it approved the NeuRx DPS RA/4 Respiratory Stimulation System, an implantable electronic device that stimulates the diaphragm and allows certain spinal cord injury patients to breathe for at least four hours a day without a mechanical ventilator.
CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk
Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).
MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment
The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.
› Verified 2 days ago
Counselors
Clinical Social Workers
Pharmacists
Dentists
Psychologists
Occupational Therapists